Sector News

Inositec names ex-Roche, Novartis staffer as CMO

January 19, 2018
Life sciences

Inositec has named former Roche and Novartis staffer Frits van Alphen, M.D., as its CMO. Van Alphen joins Inositec as the biotech gears up to move its lead vascular calcification candidate into the clinic next year.

Zurich, Switzerland-based Inositec hired van Alphen away from Roche, where he led the operational excellence team. Earlier in his career, van Alphen worked as CMO of Vifor Pharma and headed up European medical affairs at Novartis. The Novartis role also gave van Alphen responsibility for leading the company’s clinical operations team in the Netherlands. Van Alphen will now use this experience to guide Inositec into and through the clinic.

Inositec spun out of ETH Zurich late in 2015 to develop drugs based on inositol hexaphosphate. The biotech has a platform capable of replacing phosphate groups on the molecule with a view to giving them druglike properties. Inositec sees the small molecules treating a range of conditions. Vascular calcification is top of its hit list.

The small molecules advancing down the pipeline at Inositec are designed to inhibit pathological crystallization in soft tissues and thereby prevent the stiffening and blockage of arteries. If the R&D strategy goes according to plan, the drugs will have these effects regardless of the root cause of the vascular calcification, making them suitable for use in all calcification-dependent cardiovascular diseases.

Inositec is some way from clinically validating its belief in this mechanism. But with van Alphen in the CMO seat, it has taken another step toward generating supportive data.

“Dr. van Alphen is a key addition to Inositec’s team as we enter IND/CTA-enabling studies with our lead program in the vascular calcification space and fine-tune our clinical strategy in view of first-in-human studies in 2019,” Inositec CEO Mattias Ivarsson, Ph.D., said in a statement.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

March 24, 2024

Johnson Matthey to sell its Medical Devices business for $700 million

Life sciences

Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.

March 24, 2024

Lonza acquires biologics manufacturing plant in California from Roche

Life sciences

Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.

March 24, 2024

Roquette to acquire IFF Pharma Solutions to boost global excipient presence

Life sciences

Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.

How can we help you?

We're easy to reach